<DOC>
	<DOCNO>NCT01455090</DOCNO>
	<brief_summary>The purpose study estimate rate sustain virologic response ( SVR ) SVR12 , SVR12 define HCV RNA &lt; LOQ ( detectable undetectable ) 12 week post-treatment Genotype 1 &amp; Genotype 4 treatment naive patient , Genotype ( GT1 ) infect patient prior null responder pegIFN/ribavirin</brief_summary>
	<brief_title>Study Determine Effectiveness Safety Three Drug Antiviral Combination Therapy Treat Hepatitis C Virus ( HCV ) Infected Patients Not Previously Treated With Currently Available Medications</brief_title>
	<detailed_description>IND number : 79,599 ; 101,943</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Men woman , age ≥18 year age Subjects naive HCV treatment , define previous exposure Interferon ( IFN ) , Ribavirin ( RBV ) ; HCVspecific direct act antiviral experimental therapy subject null responder previous pegylated Interferon alfa ( pegIFNα ) plus Ribavirin ( RBV ) treatment Subjects chronic hepatitis C ( CHC ) document : 1 . Positive antiHCV antibody , HCV RNA , positive HCV genotype test least 6 month prior screen , positive HCV RNA AntiHCV antibody time screening , 2 . Positive antiHCV antibody HCV RNA time screen liver biopsy consistent chronic HCV infection ( liver biopsy perform prior enrollment evidence CHC disease , presence fibrosis ) HCV genotype 1a , 1b 4 HCV RNA viral load ≥10,000 IU/mL screen Have one following : 1 . Documented Fibrotest score ≤0.72 aspartate transferase ( transminase ) platelet ratio index ( APRI ) ≤2 ; OR 2 . Documented liver biopsy within 36 month precede Day 1 show absence cirrhosis OR 3 . Documented Fibroscan® ultrasound ( approve ) within 12 month screen show absence cirrhosis Body mass index ( BMI ) 18.0 35.0 kg/m2 , inclusive Subjects compensate ChildPugh A cirrhosis document history cirrhosis prior liver biopsy Fibroscan® ultrasound ( approve ) within 12 month prior screen Evidence medical condition associate chronic liver disease HCV ( limited : hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) History variceal bleeding , hepatic encephalopathy , ascites require management diuretic paracentesis Current known history cancer ( except situ carcinoma cervix adequately treat basal squamous cell carcinoma skin ) within 5 year prior enrollment Documented suspect hepatocellular carcinoma ( HCC ) Positive hepatitis B surface antigen ( HBsAg ) Positive Human Immunodeficiency Virus1 ( HIV1 ) and/or Human Immunodeficiency Virus2 ( HIV2 ) antibodies Alanine transferase ( transminase ) ( ALT ) &gt; 5x upper limit normal ( ULN ) Total Bilirubin ≥2 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>